Preventing atherosclerotic events with aspirin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial.BMJ (Clinical research ed.) · 2008
   Trial
2. Low LDL-cholesterol drives the risk of bleeding in patients treated with aspirin: A 15-year study in a real-world large population.Pharmacological research · 2025
   Article
3. Aspirin Use and Mortality in Two Contemporary US Cohorts.Epidemiology (Cambridge, Mass.) · 2018
   Article
4. Platelets: still a therapeutical target for haemostatic disorders.International journal of molecular sciences · 2014
   Review
5. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.Drugs · 2007
   Review
6. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.British journal of clinical pharmacology · 2004
   Article
7. Secondary prevention of stroke: a practical guide to drug treatment.CNS drugs · 2004
   Review
8. Changes in drug treatment in the elderly between 1971 and 2000.European journal of clinical pharmacology · 2003
   Article
9. Acute coronary disease Athero-Inflammation: Therapeutic approach.Thrombosis journal · 2003
   Article
10. Aspirin for the prevention of cardiovascular events in the elderly.Drugs & aging · 2003
    Review
11. Antiplatelet therapy and atherosclerotic events. Commentary is inaccurate.BMJ (Clinical research ed.) · 2002
    Article
12. Article makes simple errors and could cause unnecessary deaths.BMJ (Clinical research ed.) · 2002
    Article
13. Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction.BMJ (Clinical research ed.) · 2002
    Article

Corrections and comments

• Commented on by
  Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction.2002
• Comment on
  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.2002

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as